2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents

Jordan, K; Chan, A; Gralla, RJ; Jahn, F; Rapoport, B; Warr, D; Hesketh, PJ

Jordan, K (reprint author), Martin Luther Univ Halle Wittenberg, Dept Hematol Oncol, Ernst Grube Str 40, D-06120 Halle, Germany.

SUPPORTIVE CARE IN CANCER, 2017; 25 (1): 271

Abstract

Employing the same framework as in previous guideline updates, antineoplastic agents were classified into four emetic risk categories. The classificat......

Full Text Link